Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
82 hedge funds and large institutions have $146M invested in Neos Therapeutics, Inc in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 8 closing their positions.
238% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 8
168% more call options, than puts
Call options by funds: $4.74M | Put options by funds: $1.77M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
65% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 17
30% more funds holding
Funds holding: 63 → 82 (+19)
20% more capital invested
Capital invested by funds: $121M → $146M (+$24.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$5.36M |
| 2 |
BlackRock
New York
|
+$4.19M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.79M |
| 4 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$3.1M |
| 5 |
PA
Perceptive Advisors
New York
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.78M |
| 2 |
DM
Deerfield Management
New York
|
-$7.9M |
| 3 |
DA
DSC Advisors
Chicago,
Illinois
|
-$3.67M |
| 4 |
CCI
Columbus Circle Investors
|
-$1.58M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$960K |
NEOS Hedge Fund Activity: Q4 2017 in Review
82 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q4 2017, worth a combined $146M — up 20% from $121M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new NEOS positions and 8 closed out — a net gain of 19 holders — while 28 added to existing stakes and 17 trimmed.
The largest buyer was Lyon Street Capital, adding an estimated $5.36M. The largest seller was Millennium Management, exiting entirely with an estimated $9.78M sold.
- 82 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q4 2017, up from 63 in Q3 2017.
- Funds reported $146M of Neos Therapeutics, Inc stock for Q4 2017, up 20% quarter-over-quarter.
- 27 funds opened new Neos Therapeutics, Inc positions in Q4 2017 and 8 closed out, a net change of +19 holders.
- The largest Neos Therapeutics, Inc buyer in Q4 2017 was Lyon Street Capital, an estimated $5.36M added.
- The largest Neos Therapeutics, Inc seller in Q4 2017 was Millennium Management, an estimated $9.78M sold.
Based on aggregated 13F filings for Q4 2017.